ALX Oncology Holdings Inc. Common Stock – Quartalsabschluss (NASDAQ:ALXO) | MetaTrader

Vollständige Grafik anzeigen

Financials

Übersicht Finanzbericht Statistik

Vierteljährlich Jährlich

Market Capitalization 221.1 M
Employee 43
Founded 2015
CEO N/A
Website www.alxoncology.com
Headquarter Delaware, United States
FIGI BBG00VR8SDG8
Industry Technology

Gesamtumsatz

Jahresüberschuss

Unverwässertes Ergebnis je Aktie (Unverwässertes EPS)

Gesamtverschuldung

Freier Cashflow

Zahlungsmittel und Zahlungsmitteläquivalente

221.1 M Marktkapitalisierung

Nachrichten

ALX Oncology beruft Jeff Knight zum Chief Development Officer

Wells Fargo startet Coverage für ALX Oncology mit ’Overweight’-Rating

ALDX Crashes 71% as FDA Issues Third CRL for Dry Eye Disease Drug NDA

CTMX Stock Rallies on Strong Phase I Colorectal Cancer Study Data

IBRX Stock Jumps on Progress in NK Cell Therapy Production

JNJ's Bladder Cancer Therapy Meets Key Goal in Early-Stage Study

RARE's DTX301 Meets First Key Goal in Phase III OTC Deficiency Study

RLMD Stock Surges 42% in a Week: Here's What You Should Know

GSK Out-Licenses Rights for Rare Liver Disease Drug to Alfasigma

EDIT Stock Up on Narrower-Than-Expected Q4 Loss, Revenues Rise Y/Y

Roche's Giredestrant Misses Key Goal in First-Line Breast Cancer Study

LRMR Stock on the Move: What Sparked the 55% Jump in the Past Month?